Arthritis Advisory Committee
Stored: Arthritis Advisory Committee
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Arthritis Advisory Committee (AAC) is part of the U.S. Food and Drug Administration (FDA) and advises on matters concerning the treatment of arthritis, rheumatism, and related conditions. Located in Silver Spring, Maryland, the committee evaluates data on drug safety, effectiveness, and labeling related to these diseases.
Mission
The mission of the AAC is to review and evaluate data concerning drug products for arthritis and rheumatism, providing recommendations to the FDA on approval, labeling, and post-marketing surveillance. It aims to facilitate the development of safe and effective treatments for these chronic conditions.[1]
Parent organization
The AAC is part of the Food and Drug Administration (FDA), which is under the Department of Health and Human Services. The FDA is responsible for ensuring the safety, efficacy, and security of human and veterinary drugs.
Legislation
While the AAC was not established by specific legislation, it operates under the authority of the FDA, which is empowered by various acts, including the Federal Food, Drug, and Cosmetic Act.
Partners
- Pharmaceutical companies for drug application reviews
- Research institutions and universities for scientific collaboration
- Other FDA advisory committees for interdisciplinary discussions
Number of employees
The committee itself does not have permanent employees but consists of appointed members, including experts in rheumatology, orthopedics, and related fields.
Organization structure
AAC operates with:
Leader
The committee's activities are coordinated by the Designated Federal Officer (DFO).
Divisions
- Operates as a single committee without formal divisions, with members appointed for their expertise.
List of programs
- Review of new drug applications and supplements for arthritis treatments
- Joint meetings with other committees for complex drug reviews
- Public meetings to discuss broad issues in arthritis drug development
Last total enacted budget
Budget information for the AAC is not publicly disclosed, as it is part of the FDA's broader advisory committee operations.
Staff
Staff support for meetings comes from FDA personnel, but the committee members serve as external experts.
Funding
Funding for the AAC is part of the FDA's budget for advisory committee activities.
Services provided
The AAC provides scientific and technical advice on drug products related to arthritis and related conditions. This includes reviewing clinical trials, safety data, and efficacy studies, and discussing the implications for public health.[2]
Headquarters address
10903 New Hampshire Ave, Silver Spring, MD 20993
History
The Arthritis Advisory Committee has been providing advice to the FDA since its establishment, with its charter regularly renewed to reflect ongoing needs in the field of rheumatology and drug development. It plays a crucial role in the regulatory process for arthritis medications, influencing policy and drug approval decisions.
External links
References
- ↑ Food and Drug Administration (2025). "Arthritis Advisory Committee". FDA.
- ↑ Food and Drug Administration (2025). "Human Drug Advisory Committees". FDA.